A Non-Investigational Post-Market Trial Using EVARREST Fibrin Sealant Patch as an Adjunct to Hemostasis in Soft Tissue Bleeding During Intra-Abdominal, Retroperitoneal, Pelvic and Non-Cardiac Thoracic Surgery

Trial Profile

A Non-Investigational Post-Market Trial Using EVARREST Fibrin Sealant Patch as an Adjunct to Hemostasis in Soft Tissue Bleeding During Intra-Abdominal, Retroperitoneal, Pelvic and Non-Cardiac Thoracic Surgery

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Mar 2016

At a glance

  • Drugs Fibrin (Primary)
  • Indications Haemorrhage; Surgical blood loss
  • Focus Adverse reactions
  • Acronyms EVARREST PMS
  • Sponsors Ethicon
  • Most Recent Events

    • 30 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Dec 2014 According to the ClinicalTrials.gov record, planned number of patients changed from 300 to 150.
    • 03 Dec 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Aug 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top